Cartesian Therapeutics (RNAC) Total Current Liabilities (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Total Current Liabilities data on file, last reported at $15.9 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 6.31% year-over-year to $15.9 million in Q1 2026; TTM through Mar 2026 was $15.9 million, a 6.31% increase from a year earlier, with the FY2025 full-year figure at $14.9 million, down 34.99% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $15.9 million, up from $14.9 million in the prior quarter.
• Over the last five years, Total Current Liabilities for RNAC reached as high as $68.2 million in Q4 2023 and fell as low as $12.3 million in Q2 2025.
• Historically, Total Current Liabilities has averaged $26.2 million across 5 years, with a median of $23.7 million in 2022.
• Across the five-year window, Total Current Liabilities tumbled 75.18% in 2022 and jumped 172.0% in 2023, its largest moves.
• Year by year, Total Current Liabilities stood at $25.1 million in 2022, then soared by 172.0% to $68.2 million in 2023, then plunged by 66.32% to $23.0 million in 2024, then slumped by 34.99% to $14.9 million in 2025, then rose by 6.75% to $15.9 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $15.9 million in Q1 2026, $14.9 million in Q4 2025, and $13.8 million in Q3 2025.